David W Dowdy1, Jonathan E Golub, Valeria Saraceni, Lawrence H Moulton, Solange C Cavalcante, Silvia Cohn, Antonio G Pacheco, Richard E Chaisson, Betina Durovni. 1. *Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; †Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; ‡Subsecretariat for Primary Care, Surveillance, and Health Promotion, Municipal Health Secretariat, Rio de Janeiro, Brazil; §Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; ‖Program of Scientific Computing, Fiocruz, Rio de Janeiro, Brazil; ¶Evandro Chagas Institute of Clinical Research, Fiocruz, Rio de Janeiro, Brazil; and #Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Abstract
BACKGROUND: The potential epidemiological impact of isoniazid preventive therapy (IPT), delivered at levels that could be feasibly scaled up among people living with HIV (PLHIV) in modern, moderate-burden settings, remains uncertain. METHODS: We used routine surveillance and implementation data from a cluster-randomized trial of IPT among HIV-infected clinic patients with good access to antiretroviral therapy in Rio de Janeiro, Brazil, to populate a parsimonious transmission model of tuberculosis (TB)/HIV. We modeled IPT delivery as a constant process capturing a proportion of the eligible population every year. We projected feasible reductions in TB incidence and mortality in the general population and among PLHIV specifically at the end of 5 years after implementing an IPT program. RESULTS: Data on time to IPT fit an exponential curve well, suggesting that IPT was delivered at a rate covering 20% (95% confidence interval: 16% to 24%) of the 2500 eligible individuals each year. By the end of year 5 after modeled program rollout, IPT had reduced TB incidence by 3.0% [95% uncertainty range (UR): 1.6% to 7.2%] in the general population and by 15.6% (95% UR: 15.5% to 36.5%) among PLHIV. Corresponding reductions in TB mortality were 4.0% (95% UR: 2.2% to 10.3%) and 14.3% (14.6% to 33.7%). Results were robust to wide variations in parameter values on sensitivity analysis. CONCLUSIONS: TB screening and IPT delivery can substantially reduce TB incidence and mortality among PLHIV in urban, moderate-burden settings. In such settings, IPT can be an important component of a multi-faceted strategy to feasibly reduce the burden of TB in PLHIV.
RCT Entities:
BACKGROUND: The potential epidemiological impact of isoniazid preventive therapy (IPT), delivered at levels that could be feasibly scaled up among people living with HIV (PLHIV) in modern, moderate-burden settings, remains uncertain. METHODS: We used routine surveillance and implementation data from a cluster-randomized trial of IPT among HIV-infected clinic patients with good access to antiretroviral therapy in Rio de Janeiro, Brazil, to populate a parsimonious transmission model of tuberculosis (TB)/HIV. We modeled IPT delivery as a constant process capturing a proportion of the eligible population every year. We projected feasible reductions in TB incidence and mortality in the general population and among PLHIV specifically at the end of 5 years after implementing an IPT program. RESULTS: Data on time to IPT fit an exponential curve well, suggesting that IPT was delivered at a rate covering 20% (95% confidence interval: 16% to 24%) of the 2500 eligible individuals each year. By the end of year 5 after modeled program rollout, IPT had reduced TB incidence by 3.0% [95% uncertainty range (UR): 1.6% to 7.2%] in the general population and by 15.6% (95% UR: 15.5% to 36.5%) among PLHIV. Corresponding reductions in TB mortality were 4.0% (95% UR: 2.2% to 10.3%) and 14.3% (14.6% to 33.7%). Results were robust to wide variations in parameter values on sensitivity analysis. CONCLUSIONS: TB screening and IPT delivery can substantially reduce TB incidence and mortality among PLHIV in urban, moderate-burden settings. In such settings, IPT can be an important component of a multi-faceted strategy to feasibly reduce the burden of TB in PLHIV.
Authors: Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells Journal: Lancet Date: 2011-04-12 Impact factor: 79.321
Authors: C F Gilks; P Godfrey-Faussett; B I Batchelor; J C Ojoo; S J Ojoo; R J Brindle; J Paul; J Kimari; M C Bruce; J Bwayo; F A Plummer; D A Warrell Journal: AIDS Date: 1997-06 Impact factor: 4.177
Authors: C C Whalen; J L Johnson; A Okwera; D L Hom; R Huebner; P Mugyenyi; R D Mugerwa; J J Ellner Journal: N Engl J Med Date: 1997-09-18 Impact factor: 91.245
Authors: Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye Journal: Arch Intern Med Date: 2003-05-12
Authors: Molebogeng X Rangaka; Solange C Cavalcante; Ben J Marais; Sok Thim; Neil A Martinson; Soumya Swaminathan; Richard E Chaisson Journal: Lancet Date: 2015-10-26 Impact factor: 79.321
Authors: M Azadi; D M Bishai; D W Dowdy; L H Moulton; S Cavalcante; V Saraceni; A G Pacheco; S Cohn; R E Chaisson; B Durovni; J E Golub Journal: Int J Tuberc Lung Dis Date: 2014-12 Impact factor: 2.373
Authors: J Ousley; K P Soe; N T T Kyaw; R Anicete; P E Mon; H Lwin; T Win; S Cristofani; A Telnov; M Fernandez; I Ciglenecki Journal: Public Health Action Date: 2018-03-21
Authors: Emily A Kendall; Andrew S Azman; Gary Maartens; Andrew Boulle; Robert J Wilkinson; David W Dowdy; Molebogeng X Rangaka Journal: AIDS Date: 2019-03-01 Impact factor: 4.177